Regeneron Q3 2022 Earnings Report
Key Takeaways
Regeneron's Q3 2022 revenues decreased by 15% to $2.94 billion, but excluding REGEN-COV, revenues increased by 11%. EYLEA U.S. net sales increased by 11% to a record $1.63 billion, while Dupixent global net sales increased by 40% to $2.33 billion. The company reported GAAP diluted EPS of $11.66 and non-GAAP diluted EPS of $11.14.
Total revenues decreased 15% to $2.94 billion; excluding REGEN-COV, revenues increased 11%.
EYLEA U.S. net sales increased 11% to a record $1.63 billion.
Dupixent global net sales increased 40% to $2.33 billion.
GAAP diluted EPS was $11.66, and non-GAAP diluted EPS was $11.14.
Regeneron
Regeneron
Regeneron Revenue by Segment
Forward Guidance
Regeneron provided full year 2022 financial guidance for R&D, SG&A, Gross margin on net product sales, COCM, Other operating (income) expense, net, Capital expenditures, and Effective tax rate.